Organovo Holdings, Inc. ONVO
We take great care to ensure that the data presented and summarized in this overview for ORGANOVO HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ONVO
View all-
Vanguard Group Inc Valley Forge, PA354KShares$353,6120.0% of portfolio
-
Black Rock Inc. New York, NY142KShares$142,2080.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny97.8KShares$97,7870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA74.9KShares$74,9100.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il46.4KShares$46,3750.0% of portfolio
-
Morgan Stanley New York, NY42.1KShares$42,1420.0% of portfolio
-
State Street Corp Boston, MA27.8KShares$27,8310.0% of portfolio
-
Xtx Topco LTD London, X022.6KShares$22,6280.0% of portfolio
-
Raymond James & Associates St Petersburg, FL19.8KShares$19,8220.0% of portfolio
-
Ubs Group Ag15.1KShares$15,1070.0% of portfolio
Latest Institutional Activity in ONVO
Top Purchases
Top Sells
About ONVO
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Insider Transactions at ONVO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2023
|
Douglas Jay Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+28.49%
|
-
|
|
Nov 17
2023
|
Alison Tjosvold Milhous |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+33.33%
|
-
|
|
Nov 17
2023
|
Adam K Stern |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+33.33%
|
-
|
|
Nov 17
2023
|
David Gobel |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+50.0%
|
-
|
|
Nov 17
2023
|
Keith Murphy Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+14.78%
|
-
|
|
Nov 17
2023
|
Vaidehi Joshi |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+33.33%
|
-
|
|
Nov 15
2023
|
David Gobel |
SELL
Open market or private sale
|
Direct |
19,607
-100.0%
|
$19,607
$1.62 P/Share
|
|
Nov 10
2022
|
Vaidehi Joshi |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+50.0%
|
-
|
|
Nov 10
2022
|
Douglas Jay Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+39.84%
|
-
|
|
Nov 10
2022
|
Alison Tjosvold Milhous |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+50.0%
|
-
|
|
Nov 10
2022
|
Keith Murphy Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+17.35%
|
-
|
|
Nov 10
2022
|
Adam K Stern |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+50.0%
|
-
|
|
Nov 10
2022
|
David Gobel |
BUY
Grant, award, or other acquisition
|
Direct |
19,607
+50.0%
|
-
|
|
Aug 17
2021
|
Douglas Jay Cohen |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$12,000
$6.73 P/Share
|
|
Aug 17
2021
|
Douglas Jay Cohen |
BUY
Open market or private purchase
|
Direct |
8,750
+46.67%
|
$52,500
$6.72 P/Share
|
|
Mar 08
2021
|
Keith Murphy Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+23.17%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 118K shares |
|---|
| Open market or private sale | 19.6K shares |
|---|